Hints and tips:
Related Special Reports
...Amanda Pritchard, chief executive of NHS England, said GPs were “working incredibly hard to deal with unprecedented demand for appointments”....
...Eli Lilly, the world’s largest drugmaker by market value, has struck a deal that will allow Amazon’s online pharmacy business to dispense medication, including its hugely popular weight loss injection pen...
...Adam Fein, president of Drug Channels Institute, said Amazon Pharmacy “continues to garner attention . . . beyond its actual impact on the pharmacy industry”....
...This deal is being forced on Japan by demographics, but the idea applies more widely....
...The deal helped Sistani and her team increase full-year subscriber numbers for the first time in three years to 3.8mn, up 7 per cent from 2022....
...J&J’s medtech division has outstripped the growth of the company’s drugs and diagnostics business, generating $30.4bn in sales last year, or 35 per cent of group revenues....
...This deal comes after Roche announced a partnership with Alnylam worth up to $2.8bn to work together on an innovative medicine for hypertension....
...The FTC had contended that Amgen could get buyers such as health insurers or pharmacy benefit managers to favour Horizon’s drugs by bundling them with its own best-selling medicines....
...CVS Health, the largest pharmacy chain in the US, in 2018 acquired Aetna for $69bn and Cigna combined with Express Scripts in a $67bn deal, including debt....
...loss drugs Ozempic and Wegovy....
...The FTC’s detailed opposition to the Horizon deal focuses on so-called pharmacy benefit managers. These businesses determine which drug prescriptions are eligible for health insurance reimbursement....
...For example, Nordic Capital made around seven times its money when it sold vet care business AniCura to Mars in a €2bn deal....
...It seems the previous Duke of Halstead had struck a deal with a crime family allowing them to build a clandestine cannabis farm under the property’s land....
...Rival pharmaceutical groups are eager to enter the market, including AstraZeneca, which recently signed a licensing deal with Chinese company Eccogene for the rights to its weight loss pill....
...The FTC argued that Amgen could use the rebates it pays on its existing “blockbuster” drugs to press insurance companies and pharmacy benefit managers into paying for two of Horizon’s medicines: Tepezza...
...Its — untested — argument is that Amgen could use rebates on its blockbusters to encourage insurers and pharmacy benefit managers to favour Horizon’s drugs....
...It required the six largest pharmacy benefit managers, which negotiate fees and rebates with drug manufacturers, to share information on their business practices....
...The FTC argued that Amgen could use the rebates it pays on its “blockbuster” drugs to press insurance companies and pharmacy benefit managers into paying for two of Horizon’s medicines: Tepezza for an autoimmune...
...Amgen is offering two pricing plans because in the complex US healthcare system — where the real cost of a drug tends to be decided via opaque deals — some pharmacy benefit managers prefer higher list prices...
...The deal does not point to an increase in exploration....
...Easy capital is a powerful drug. Its side effects include myopia....
...News round-up UAE planned to use COP28 summit for oil deals, documents show (FT) Abu Dhabi’s media record under scrutiny after Telegraph deal offer (FT) Bayer chief blames thin drug pipeline on ‘years...
...In its first challenge to a pharmaceutical deal in more than a decade, Khan’s Federal Trade Commission had sought to block the deal, arguing greater market power would lead to higher prices for patients....
...It deployed a novel argument, claiming the transaction would enable Amgen to use rebates on its existing blockbuster drugs to pressure insurance companies and pharmacy benefit managers into favouring Horizon...
International Edition